Moxyplant CV 228.5 Dry Syrup contains Amoxycillin 200mg + Clavulanic Acid 28.5mg, a broad-spectrum pediatric antibiotic indicated for bacterial infections of the respiratory tract, ENT, urinary tract, and soft tissues. It helps alleviate infection symptoms and supports rapid recovery in children.
Amoxycillin inhibits bacterial cell wall synthesis, while Clavulanic Acid protects Amoxycillin from beta-lactamase degradation, enhancing its effectiveness against resistant bacteria. This combination ensures powerful antibacterial activity for pediatric infections.
The dry syrup formulation allows accurate dosing, ease of administration, and better compliance for children. Moxyplant CV 228.5 Dry Syrup is widely recommended by pediatricians for mild to moderate infections, making it a high-demand pediatric antibiotic product.
Adding Moxyplant CV 228.5 Dry Syrup to your pediatric antibiotic segment strengthens your portfolio with a trusted combination therapy. Its prescriber preference, steady demand, and applicability for domestic and export markets make it a valuable addition to pharmaceutical distribution portfolios.